In patients with Philadelphia chromosome (Ph)-positive B-cell acute lymphoblastic leukemia who experience relapse after consolidation with allogeneic hematopoietic cell transplantation (HCT), ...

Among the efficacy evaluable patients, 42% achieved complete remission within 3 months. The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the ...

A gentler treatment for children whose leukemia has come back could boost survival and quality of life, a study led by a UCL ...

Scientists from St. Jude Children's Research Hospital, Seattle Children's and the Children's Oncology Group (COG) have identified novel genetic variations that influence relapse risk in children with ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...

Scientists from the Children’s Hospital of Philadelphia (CHOP) report that they have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a ...

Simulation-Based Evaluation of a Large Language Model–Enabled Clinical Decision Support Platform in Oncology PREPARE-ALL was developed using data from the ICiCLe ALL-14 pretrial cohort across five ...

Precursor B-cell acute lymphoblastic leukemia is a fast-growing leukemia that affects early B cells in bone marrow. It’s both more common and has a better outlook in children. Leukemia is a type of ...

Predicting Change in Academic Abilities After Conformal Radiation Therapy for Localized Ependymoma One hundred twenty-four patients with ALL and first marrow relapse received three, 35-day blocks of ...

Kevin Liu was diagnosed with acute lymphoblastic leukemia, which spread to his brain, in 2022. He documented his appearance ...